Your browser is no longer supported. Please, upgrade your browser.
Fusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)- Insider Own9.03% Shs Outstand41.68M Perf Week-3.68%
Market Cap482.29M Forward P/E- EPS next Y-0.44 Insider Trans-0.22% Shs Float31.88M Perf Month-1.83%
Income- PEG- EPS next Q-0.19 Inst Own80.10% Short Float1.06% Perf Quarter-10.93%
Sales- P/S- EPS this Y-38.90% Inst Trans5.14% Short Ratio5.49 Perf Half Y-12.72%
Book/sh7.35 P/B1.53 EPS next Y83.90% ROA- Target Price- Perf Year-
Cash/sh6.81 P/C1.65 EPS next 5Y- ROE- 52W Range10.51 - 19.00 Perf YTD-4.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.79% Beta-
Dividend %- Quick Ratio55.90 Sales past 5Y- Gross Margin- 52W Low7.04% ATR0.60
Employees41 Current Ratio55.90 Sales Q/Q- Oper. Margin- RSI (14)39.84 Volatility3.90% 5.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-189.00% Profit Margin- Rel Volume0.53 Prev Close11.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume61.46K Price11.25
Recom1.60 SMA20-5.77% SMA50-5.77% SMA200-12.79% Volume32,622 Change-1.57%
Jul-21-20Initiated Wedbush Outperform $25
Jul-21-20Initiated Jefferies Buy $25
Jul-21-20Initiated Cowen Outperform
Mar-02-21 07:30AM  
Feb-23-21 04:30PM  
Feb-11-21 08:00AM  
Jan-25-21 12:40AM  
Jan-22-21 01:39PM  
Jan-11-21 07:30AM  
Dec-16-20 09:00AM  
Dec-10-20 06:24PM  
Nov-26-20 12:36AM  
Nov-12-20 04:10PM  
Nov-10-20 07:00AM  
Nov-02-20 04:10PM  
Oct-27-20 03:30PM  
Sep-29-20 04:15PM  
Sep-27-20 10:18AM  
Sep-10-20 09:00AM  
Aug-11-20 07:25AM  
Aug-05-20 08:00AM  
Jul-14-20 09:30AM  
Jul-10-20 05:13PM  
Jun-25-20 10:39PM  
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAMS STREET PARTNERS LLC10% OwnerDec 24Sale12.323,80046,816418,190Dec 29 04:01 PM
ADAMS STREET PARTNERS LLC10% OwnerDec 23Sale12.394,56956,610418,645Dec 28 04:02 PM